Table 12.6a

Immunosuppression Use for Induction, 1994 to 2003

Recipients with Lung Transplants

	Year of Transplant
	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
Transplants	738	893	836	946	893	920	977	1,083	1,054	1,099
Tx With Immunosuppression Info	729	879	764	929	886	894	950	1,065	1,030	1,085
No Induction Drugs Recorded	74.8%	71.4%	73.8%	78.1%	77.5%	69.5%	56.9%	61.1%	56.3%	55.9%
Drugs	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ALG
ATG/NRATG/NRATS	19.1%	23.3%	22.6%	19.6%	13.9%	12.6%	11.9%	8.8%	6.4%	4.9%
OKT3	6.2%	5.2%	3.7%	2.5%	3.5%	3.4%	2.6%	1.0%	0.6%	1.1%
Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	1.9%	6.0%	5.4%	8.3%	3.0%
Zenapax	0.0%	0.0%	0.0%	0.0%	4.9%	9.6%	14.6%	11.3%	13.7%	15.7%
Simulect	0.0%	0.0%	0.0%	0.0%	0.3%	3.2%	8.3%	12.8%	15.0%	19.4%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%

Source: OPTN/SRTR Data as of May 3, 2004.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.